These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24506342)

  • 21. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
    Goodwin GM; Emsley R; Rembry S; Rouillon F;
    J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients.
    Quera-Salva MA; Lemoine P; Guilleminault C
    Hum Psychopharmacol; 2010 Apr; 25(3):222-9. PubMed ID: 20373473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The importance of early symptom relief in antidepressant treatment: focus on agomelatine.
    Lam RW
    J Psychopharmacol; 2010 Aug; 24(2 Suppl):27-30. PubMed ID: 20663806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of agomelatine in OCD: effects on the motivational aspects and dysregulated circadian rhythms.
    Perugi G; Quaranta G; Bucci N
    Expert Opin Investig Drugs; 2015 May; 24(5):705-13. PubMed ID: 25727766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Agomelatine Effectiveness, Tolerability, and Impact on Anhedonia in Major Depression: A Pooled Analysis.
    di Giannantonio M; Montemitro C; Sepede G; Brunetti M; Baroni G; Corbo M; Anders M; Tavčar R; Martinotti G; Manzoli L
    J Clin Psychopharmacol; 2019; 39(3):288-290. PubMed ID: 30932949
    [No Abstract]   [Full Text] [Related]  

  • 26. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
    Demyttenaere K; Corruble E; Hale A; Quera-Salva MA; Picarel-Blanchot F; Kasper S
    CNS Spectr; 2013 Jun; 18(3):163-70. PubMed ID: 23472671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disturbances of diurnal phase markers, behavior, and clock genes in a rat model of depression; modulatory effects of agomelatine treatment.
    Højgaard K; Christiansen SL; Bouzinova EV; Wiborg O
    Psychopharmacology (Berl); 2018 Mar; 235(3):627-640. PubMed ID: 29151193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The mechanism, efficacy, and tolerability profile of agomelatine.
    MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spike-Wave Discharges and Sleep-Wake States during Circadian Desynchronization: No Effects of Agomelatine upon Re-Entrainment.
    Smyk MK; van Luijtelaar G; Huysmans H; Drinkenburg WH
    Neuroscience; 2019 Jun; 408():327-338. PubMed ID: 30978380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treating each and every depressed patient.
    Kennedy SH
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Agomelatine's effect on circadian locomotor rhythm alteration and depressive-like behavior in 6-OHDA lesioned rats.
    Souza LC; Martynhak BJ; Bassani TB; Turnes JM; Machado MM; Moura E; Andreatini R; Vital MABF
    Physiol Behav; 2018 May; 188():298-310. PubMed ID: 29458117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
    Shu L; Sulaiman AH; Huang YS; Fones Soon Leng C; Crutel VS; Kim YS
    Asian J Psychiatr; 2014 Apr; 8():26-32. PubMed ID: 24655622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
    Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
    J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agomelatine: efficacy at each phase of antidepressant treatment.
    Kennedy SH
    CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine.
    Pandi-Perumal SR; Moscovitch A; Srinivasan V; Spence DW; Cardinali DP; Brown GM
    Prog Neurobiol; 2009 Aug; 88(4):264-71. PubMed ID: 19454302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melatonergic drugs in clinical practice.
    Hardeland R; Poeggeler B; Srinivasan V; Trakht I; Pandi-Perumal SR; Cardinali DP
    Arzneimittelforschung; 2008; 58(1):1-10. PubMed ID: 18368944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
    San L; Arranz B
    Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerance profile of agomelatine and practical use in depressed patients.
    Rouillon F
    Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S31-5. PubMed ID: 16436938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study.
    Englisch S; Jung HS; Lewien A; Becker A; Nowak U; Braun H; Thiem J; Eisenacher S; Meyer-Lindenberg A; Zink M
    J Clin Psychopharmacol; 2016 Dec; 36(6):597-607. PubMed ID: 27805978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.
    Kennedy SH; Rizvi S; Fulton K; Rasmussen J
    J Clin Psychopharmacol; 2008 Jun; 28(3):329-33. PubMed ID: 18480691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.